Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 17/20 | 0.62 |
| ▸ | HTR2B | P41595 | 16/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283064 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL3283555 | 1.00 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Hydrochloric Acid SCHEMBL3246468 | 0.98 | HTR2C (0.97) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL3283040 | 0.77 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL3282305 | 0.77 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL3282302 | 0.77 | HTR2C (1.00) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| SCHEMBL16835251 | 0.76 | HTR2C (0.61) | HTR2CADRA2C | |
| SCHEMBL1010578 | 0.76 | HTR2C (0.61) | HTR2CHTR2AHTR2BPNMT | |
| Bromide SCHEMBL16241877 | 0.75 | HTR2C (0.60) | HTR2CADRA2C | |
| SCHEMBL6484273 | 0.74 | HTR2C (0.58) | HTR2CHTR2AHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8404675-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5HT2C receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. | 2010-07-08 | — | — | US | disclosed |
| US-7704993-B2 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173894-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, TPH2, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 4/4885 |
| US-20130172322-A1 | BENZAZEPINE DERIVATIVES USEFUL FOR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | HTR2C, HTR2A, TPH2 | HTR2C 1/4885HTR2A 2/4885HTR2B 4/4885 |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, TPH2, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.